Industry Publications and Presentations

From telemedicine to remote site visits: the post-COVID face of pharma research and development

The acute phase of the COVID-19 pandemic not only brought delays, restrictions, and reconfigurations to pharmaceutical research & development in 2020, but also a more flexible response to some long-standing issues with the clinical trials process. Read our article, in collaboration with pharmaphorum, to learn more.

Read More
Decentralized Clinical Trials (DCTs): Five Key Questions to Ask Your Partners to Optimize Strategy

This article addresses five essential questions clinical research partners should discuss with sponsors, sites and regulators in order to optimize the strategy and implementation of decentralized and hybrid trial models.

Read More
Five Recommendations to Make Trials More Child-Centric

While rare diseases individually affect a relatively small number of patients, as a category these diseases affect millions of people – and half of those patients are children. This article addresses why it's important to design child-centric trials to accelerate rare disease research.

Read More
Planning a Decentralized Clinical Trial

Learn how both CROs and sponsors can benefit from decentralized trial models.

Read More
Raconteur Magazine – The Future of Healthcare

Explore Graham Belgrave's comments on the challenging ethics to find a vaccine.

Read More
Future Forward Trends for Overcoming the Talent Shortage while Diminishing Risk (Innovation Theater – DIA 2020)

Learn how to proactively address the talent shortage with the right recruitment model.

Read More
Solving Immuno-Oncology Trial Challenges in the COVID-19 Era

The COVID-19 pandemic has stressed healthcare provision, but may also make major advances even more relevant.

Read More
Effective Design and Implementation of Sponsor / CRO Governance

Learn why governance boards are important, especially in the face of a pandemic like COVID-19.

Read More
A New Remote Reality

Learn why clinical operations will swiftly become a new "remote reality," especially amidst a pandemic like COVID-19.

Read More
Addressing E6 (R2) as an SMB

Learn why SMBs may be falling behind on the heels of the E6(R2) addendum and how you can adapt your team.

Read More